Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zolodine Switching in Schizophrenia Patients with Metabolic Syndrome
NCT04975035Phase 2Terminated
- Sponsor
- Second Affiliated Hospital of Zhejiang University School of Medicine
- Start
- Jan 2012
- Primary completion
- Jul 2012
- Modality
- Small Molecules
01
Overview
Phase 2, open-label, single-arm trial of ziprasidone in schizophrenia, sponsored by Second Affiliated Hospital of Zhejiang University School of Medicine. Primary endpoints: Positive and Negative Syndrome Scale at 2 weeks, Hamilton Anxiety Rating Scale at 2 weeks and 1 more. Started Jan 2012; status: terminated.
02
Drugs
ziprasidone
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT04975035.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04975035.